Systematic review and meta-analysis of anti-CD20 treatments in patients with COVID-19: an assessment of severe illness and mortality outcomes
ConclusionHealthcare practitioners should exercise caution when prescribing these anti-CD20 monoclonal antibodies during the COVID-19 pandemic to patients who are indicated for these agents, particularly those with underlying conditions like multiple sclerosis or rheumatoid arthritis.
Source: Inflammopharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Coronavirus | COVID-19 | Databases & Libraries | Drugs & Pharmacology | Multiple Sclerosis | Pandemics | Rheumatoid Arthritis | Rheumatology | Rituxan | Sports Medicine | Study